Experts discuss how biomarker testing results should be reassessed or expanded upon disease progression and how they guide the selection of second-line therapies or clinical trial enrollment.
How should biomarker testing results be reassessed or expanded upon disease progression, and how do they guide the selection of second-line therapies or clinical trial enrollment?